The anti-tumour necrosis factor (TNF)-α adalimumab is the only licenced biologic for moderate-to-severe hidradenitis suppurativa (HS). No predictors of response have been identified so far.

Evidence for a 'window of opportunity' in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study / Marzano, A V; Genovese, G; Casazza, G; Moltrasio, C; Dapavo, P; Micali, G; Sirna, R; Gisondi, P; Patrizi, A; Dini, V; Bianchini, D; Bianchi, L; Fania, L; Prignano, F; Offidani, A; Atzori, L; Bettoli, V; Cannavò, S P; Venturini, M; Bongiorno, M R; Costanzo, A; Fabbrocini, G; Peris, K. - In: BRITISH JOURNAL OF DERMATOLOGY. - ISSN 1365-2133. - 184:1(2021), p. 133-140. [10.1111/bjd.18983]

Evidence for a 'window of opportunity' in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study

Genovese, G;Bianchi, L;Fabbrocini, G;
2021

Abstract

The anti-tumour necrosis factor (TNF)-α adalimumab is the only licenced biologic for moderate-to-severe hidradenitis suppurativa (HS). No predictors of response have been identified so far.
2021
Evidence for a 'window of opportunity' in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study / Marzano, A V; Genovese, G; Casazza, G; Moltrasio, C; Dapavo, P; Micali, G; Sirna, R; Gisondi, P; Patrizi, A; Dini, V; Bianchini, D; Bianchi, L; Fania, L; Prignano, F; Offidani, A; Atzori, L; Bettoli, V; Cannavò, S P; Venturini, M; Bongiorno, M R; Costanzo, A; Fabbrocini, G; Peris, K. - In: BRITISH JOURNAL OF DERMATOLOGY. - ISSN 1365-2133. - 184:1(2021), p. 133-140. [10.1111/bjd.18983]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/849782
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 86
  • ???jsp.display-item.citation.isi??? 82
social impact